美国胚胎植入前非整倍体遗传学检测的成本效益:基于158,665个IVF周期的分析
该研究基于美国SART国家登记数据2014-2016年114,157个首次新鲜IVF刺激和44,508个关联冻胚移植周期,构建概率决策树模型,从患者和支付方视角分析胚胎植入前非整倍体遗传学检测(PGT-A)的成本效益。结果显示PGT-A的成本效益取决于患者年龄和视角,不应普遍采用常规PGT-A。
要点
- 35岁以下患者PGT-A临床结局更差且费用更高。
- 35岁及以上患者PGT-A累积活产更多但费用更高。
- 患者视角下39岁起PGT-A更具成本效益,支付方视角下各年龄均倾向PGT-A。
核心结论
- PGT-A的成本效益取决于患者年龄和分析视角,不应普遍常规采用,但特定情景下可能具有成本效益。
研究设计与样本
- 基于美国SART国家登记数据2014-2016年IVF周期的概率决策树分析。
- 研究人群包括114,157个首次新鲜IVF刺激和44,508个关联冻胚移植周期。
- 比较两种策略:有意行PGT-A的IVF与移植未检测胚胎的IVF。
- 患者进展至活产或卵巢刺激后12个月,成本从患者和支付方视角提取自文献。
主要发现
- 新鲜刺激周期中16.2%有意行PGT-A,83.8%未行。
- 35岁以下患者PGT-A与更差临床结局和更高费用相关。
- 35岁及以上患者PGT-A带来更多累积活产但两个视角费用均更高。
- 患者视角下增量成本每活产在<35岁至38岁组偏向无PGT-A策略,39岁起偏向PGT-A。
- 支付方视角下增量成本每活产不论年龄均偏向PGT-A。
关键数值与推荐
- 结局指标包括增量成本(2018年美元)、活产结局、增量成本效果比和增量成本每活产。
- 患者视角下39岁起PGT-A的增量成本每活产更优。
- 支付方视角下各年龄PGT-A的增量成本每活产均更优。
临床怎么用
- 临床决策应结合患者年龄和支付视角个体化评估PGT-A的成本效益。
- 不应对所有不孕症患者常规推荐PGT-A。
- 39岁及以上患者从患者视角可考虑PGT-A以改善成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A controversial and unresolved question in reproductive medicine is the utility of preimplantation genetic testing for aneuploidy as an adjunct to in vitro fertilization. Infertility is prevalent, but its treatment is notoriously expensive and typically not covered by insurance. Therefore, cost-effectiveness is critical to consider in this context. OBJECTIVE: This study aimed to analyze the cost-effectiveness of preimplantation genetic testing for aneuploidy for the treatment of infertility in the United States. STUDY DESIGN: As reported to the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System, a national data registry, in vitro fertilization cycles occurring between 2014 and 2016 in the United States were analyzed. A probabilistic decision tree was developed using empirical outputs to simulate the events and outcomes associated with in vitro fertilization with and without preimplantation genetic testing for aneuploidy. The treatment strategies were (1) in vitro fertilization with intended preimplantation genetic testing for aneuploidy and (2) in vitro fertilization with transfers of untested embryos. Patients progressed through the treatment model until they achieved a live birth or 12 months after ovarian stimulation. Clinical costs related to both treatment strategies were extracted from the literature and considered from both the patient and payer perspectives. Outcome metrics included incremental cost (measured in 2018 US dollars), live birth outcomes, incremental cost-effectiveness ratio, and incremental cost per live birth between treatment strategies. RESULTS: The study population included 114,157 first fresh in vitro fertilization stimulations and 44,508 linked frozen embryo transfer cycles. Of the fresh stimulations, 16.2% intended preimplantation genetic testing for aneuploidy and 83.8% did not. In patients younger than 35 years old, preimplantation genetic testing for aneuploidy was associated with worse clinical outcomes and higher costs. At age 35 years and older, preimplantation genetic testing for aneuploidy led to more cumulative births but was associated with higher costs from both perspectives. From a patient perspective, the incremental cost per live birth favored the no preimplantation genetic testing for aneuploidy strategy from the <35 years age group to the 38 years age group and beginning at age 39 years favored preimplantation genetic testing for aneuploidy. From a payer perspective, the incremental cost per live birth favored preimplantation genetic testing for aneuploidy regardless of patient age. CONCLUSION: The cost-effectiveness of preimplantation genetic testing for aneuploidy is dependent on patient age and perspective. From an economic perspective, routine preimplantation genetic testing for aneuploidy should not be universally adopted; however, it may be cost-effective in certain scenarios.
引用
- Lee M, Lofgren KT, Thomas A, et al. The cost-effectiveness of preimplantation genetic testing for aneuploidy in the United States: an analysis of cost and birth outcomes from 158,665 in vitro fertilization cycles. Am J Obstet Gynecol. 2021. PMID: 33539823. doi:10.1016/j.ajog.2021.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。